Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YY001 for Moderate to Severe Glabellar Lines
NCT05743634Phase 2Completed
- Sponsor
- Claruvis Pharmaceutical
- Start
- Mar 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of YY001 in glabellar lines, sponsored by Claruvis Pharmaceutical. Started Mar 2022; status: completed.
02
Drugs
YY001
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT05743634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05743634.